A high-risk, high-reward clinical-stage biotech firm investing heavily in R&D to advance a proprietary pipeline of targeted cancer therapies while maintaining minimal current revenue operations.
Investors may view Passage BIO as a compelling opportunity if its proprietary ADC platform demonstrates efficacy in pivotal trials, potentially unlocking massive value from its current $37.6M cash position and paid-in capital of $720.5M. The company's ability to leverage significant non-cash adjustments ($14.4M) and manage long-term lease liabilities suggests disciplined financial stewardship relative to typical biotech peers.
The stock carries extreme downside risk due to a decade-long history of losses, with net income deteriorating from -$136.1M in 2022 to -$64.8M in 2024 without any revenue generation. The absence of current assets beyond cash and equivalents ($78.8M total) and zero operating profit indicates a business model that cannot currently sustain itself without continuous equity or debt financing.
Passage BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology, immunology, and metabolic diseases, primarily serving markets in the United States through its proprietary antibody-drug conjugate platform.
Management has maintained a lean operational structure with no cost of revenue or gross profit, resulting in substantial operating losses driven by heavy investments in research ($40.2M) and administrative functions ($25.0M). Despite generating positive cash flow from investing activities via marketable security proceeds of $143.2M, the company continues to burn cash at a rate of approximately $65M annually, raising concerns about liquidity runway.
The biopharmaceutical industry is characterized by high barriers to entry, intense competition from large pharmaceutical firms, and a regulatory landscape requiring extensive clinical trials before market approval. Companies in this sector often operate with negative earnings for years while racing to secure intellectual property rights and FDA approval for novel therapies.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $138.4M | $108.4M | $70.4M |
| Operating Income | $-138.4M | $-108.4M | $-70.4M |
| R&D | — | — | $40.2M |
| G&A | $49.3M | $41.6M | $25.0M |
| Stock-Based Comp | $19.0M | $10.9M | $5.8M |
| D&A | $3.7M | $3.7M | $3.1M |
| Other OpEx | $89.1M | $66.8M | $5.2M |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-138.4M | $-108.4M | $-70.4M |
| Income Tax | $-2.3M | $-6.3M | $-5.6M |
| Continuing Ops | $-136.1M | $-102.1M | $-64.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-136.1M | $-102.1M | $-64.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-136.1M | $-102.1M | $-64.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $197.0M | $118.0M | $78.8M |
| Cash & Equivalents | $34.6M | $21.7M | $37.6M |
| Prepaid Expenses | $926.0K | $923.0K | $838.0K |
| Other Current Assets | $161.5M | $95.3M | $40.4M |
| Long-Term Assets | $46.5M | $32.6M | $23.6M |
| PP&E (Net) | $22.5M | $15.3M | $9.3M |
| Operating Leases | $19.7M | $16.9M | $13.8M |
| Other LT Assets | $4.3M | $433.0K | $463.0K |
| Total Assets | $243.5M | $150.5M | $102.4M |
| Current Liabilities | $18.4M | $16.3M | $19.4M |
| Accounts Payable | $4.1M | $1.3M | $742.0K |
| Current Leases | $3.3M | $3.4M | $3.7M |
| Deferred Revenue | — | — | $8.2M |
| Other Current Liab | $11.0M | $11.7M | $6.7M |
| Long-Term Liabilities | $23.8M | $22.9M | $21.8M |
| LT Operating Leases | $23.8M | $22.9M | $21.8M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $42.2M | $39.3M | $41.2M |
| Shareholders' Equity | $201.4M | $111.3M | $61.3M |
| Paid-In Capital | $694.7M | $705.8M | $720.5M |
| Retained Earnings | $-492.4M | $-594.5M | $-659.2M |
| AOCI | $-966.0K | $-43.0K | $8.0K |
| Total L&E | $243.5M | $150.5M | $102.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-136.1M | $-102.1M | $-64.8M |
| Non-Cash Adjustments | $26.1M | $29.8M | $14.4M |
| Working Capital Changes | $-8.1M | $-6.0M | $2.5M |
| Cash from Operations | $-118.2M | $-78.3M | $-48.0M |
| Cash from Investing | $25.2M | $65.2M | $54.9M |
| Cash from Financing | $-1.4M | $135.0K | $8.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-94.4M | $-12.9M | $15.9M |
| Beginning Cash | $129.0M | $34.6M | $21.7M |
| Ending Cash | $34.6M | $21.7M | $37.6M |
The company operates through a single integrated business segment dedicated to drug discovery and development, channeling all financial resources into Research and Development expenses ($40.2M) and General & Administrative costs ($25.0M) rather than traditional product sales segments.
Significant cash burn indicated by net income losses of -$64.8M in 2024 and cumulative deficits exceeding -$659M; complete reliance on external capital markets given zero revenue and cost of goods sold; potential dilution from financing activities despite recent cash inflows; and the high attrition risk typical of clinical-stage biotechnology ventures.
The firm leverages a proprietary antibody-drug conjugate (ADC) platform designed to improve the selectivity and efficacy of cancer treatments, potentially offering a significant technological moat once clinical milestones are achieved.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.